Prolactin and autoimmune diseases in humans

Acta Biomedica

Volumn 78, Issue SUPPL. 1, 2007, Pages 255-261

  Chuang, Ellie ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autoimmune disease; Hyperprolactinemia; Prolactin; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

AMINOQUINOLINE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; CYCLOSPORIN; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PENICILLAMINE; PREDNISONE; PROLACTIN; PROLACTIN RECEPTOR; QUINAGOLIDE;

ANIMAL; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; GENETICS; HUMAN; HYPERPROLACTINEMIA; IMMUNOLOGY; MALE; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

AMINOQUINOLINES; ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BROMOCRIPTINE; CYCLOSPORINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, KNOCKOUT; PENICILLAMINE; PREDNISONE; PROLACTIN; RATS; RECEPTORS, PROLACTIN;

EID: 34347267278     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Smith P. The effect of hypophysectomy upon the involution of the thymus in the rat. Anat Rec 1930; 47: 119-29.
2. Russell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci 1989; 10: 40-4.
3. Horseman ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev 1994; 15: 627-49.
4. Clevenger C, Sillman A, Hanley-Hyde J, Prystowsky M. Requirement for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes. Endocrinology 1992; 130: 3216-22.
5. Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J Clin Invest 2003; 111: 275-83.
6. Stevens A, Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene-implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 2001; 10: 676-83.
7. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 1997; 4: 171-80.
8. Jara LJ, Lavalle C, Fraga A, et al. Prolactin, immunoregulation, and autoimmune diseases. Sem Arthritis Rheum 1991; 20: 273-84.
9. Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1890-900.
10. Miayi K, Ichihara K, Kondo K, Mori S. Asymptomatic hyperprolactinaemia and prolactinoma in general population-mass screening by paired assays of serum prolactins. Clin Endocrinol 1986; 25: 549-54.
11. Fahie-Wilson M. In hyperprolactinaemia, testing for macroprolactin is essential. Clin Chem 2003; 49: 1434-36.
12. Nagy E, Berczi I, Friesen HG. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh) 1983; 102: 351-57.
13. Berczi I, Nagy E, de Toledo S, Matusik R, Friesen HG. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J Immunol 1991; 146: 2201-6.
14. Bernton E, Meltzer M, Holaday J. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science 1988; 239: 401-4.
15. Berczi I, Nagy E. The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum 1984; 27: 682-88.
16. McMurray R, Keisler D, Izui S, Walker SE. Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 1994; 71: 338-43.
17. McMurray R. Bromocriptine in rheumatic and autoimmune diseases. Sem Arthritis Rheum 2001; 31: 21-32.
18. Yu-Lee L-Y. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002; 57: 435-55.
19. Dorshkind K, Horseman N. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000; 21: 292-312.
20. Azad N, Agrawal L, Emanuele MA, et al. Neuroimmunoendocrinology. Am J Reprod Immunol 1991; 26: 160-72.
21. Smith E. Hormonal activities of cytokines. In: Blalock J, ed: Neuroimmunoendocrinology. S. Karger, Basel, 1992:154-69.
22. Mandrup-Poulsen T, Nerup J, Reimers JI, et al. Cytokines and the endocrine system. I. The immunoendocrine network. Eur J Endocrinol 1995; 133: 660-71.
23. Gerli R, Riccardi C, Nicoletti I, et al. Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia. J Clin Immunol 1987; 7: 463-70.
24. Vidaller A, Llorente L, Larrea F, Mendez JP, Alcocer-Varela J, Alarcon-Segovia D. T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment. Clin Immunol Immunopathol 1986; 38: 337-43.
25. Vidaller A, Guadarrama F, Llorente L, et al. Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J Clin Immunol 1992; 12: 210-5.
26. Fornari M, Palacio M, Diez R, Intebi A. Decreased chemotaxis of neutrophils in acromegaly and hyperprolactinemia. Eur J Endocrinol 1994; 130: 463-68.
27. Sabharwal P, Zwilling B, Glaser R, Malarkey WB. Cellular immunity in patients with acromegaly and prolactinomas. Prog NeuroEndocrinImmunol 1992; 5: 120-25.
28. Ishibashi M, Kuzuya N, Sawada S, Kitamura K, Kamoi K, Yamaji T. Anti-thyroid antibodies in patients with hyperprolactinemia. Endocrinol Jpn 1991; 38: 517-22.
29. Buskila D, Berezin M, Gur H, et al. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun 1995; 8: 415-24.
30. Walker S, Jacobson J. Neuroendocrine mechanisms in rheumatic diseases: Roles of prolactin and gonadatropin-releasing hormone in rheumatic diseases. Rheum Dis Clin North Am 2000; 26: 713-36.
31. Jara LJ, Silveira LH, Cuellar ML, Pineda CJ, Scopelitis E, Espinoza LR. Hyperprolactinemia in Reiter's syndrome. J Rheumatol 1994; 21: 1292-7.
32. Haga H-J, Rygh T. The prevalence of hyperprolactinemia in patients with primary Sjogren's syndrome. J Rheumatol 1999; 26: 1291-95.
33. Giasuddin A, El-Sherif A, El-Ojali S. Prolactin: does it have a role in the pathogenesis of psoriasis? Dermatology 1998; 197: 119-22.
34. Rovensky J, Jurankova E, Rauova L, et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 2330-4.
35. Moszkorzova L, Lacinova Z, Marek J, Musilova L, Dohnalova A, Dostal C. Hyperprolactinaemia in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2002; 20: 807-12.
36. Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 1992; 303: 222-6.
37. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001; 10: 554-61.
38. Leanos A, Pascoe D, Fraga A, Blanco-Favela F. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus 1998; 7: 398-403.
39. Blanco-Favela F, Chavez-Rueda K, Leanos-Miranda A. Analysis of anti-prolactin autoantibodies in systemic lupus erythematosus. Lupus 2001; 10: 757-61.
40. Leanos-Miranda A, Chavez-Rueda K, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 866-75.
41. Larrea F, Martinez-Castillo A, Cabrera V, et al. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J Clin Endocrinol Metab 1997; 82: 3664-9.
42. Jacobi AM, Rohde W, Volk HD, Dorner T, Burmester GR, Hiepe F. Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls. Ann Rheum Dis 2001; 60: 242-7.
43. Vera-Lastra O, Mendez C, Jara LJ, et al. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol 2003; 30: 2140-46.
44. McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995; 22: 2084-91.
45. Hrycek A, Cieslik P, Tustanowski J, Nowak S, Jedynak P. Selected serum cytokines in systemic lupus erythematosus treated with quinagolide. Lupus 2001; 10: 424-30.
46. Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998; 7: 414-9.
47. Walker SE, Reddy G, Yangco D, Kalanje S, Abdou N, et al. Treatment of active systemic lupus erythematosus (SLE) with the prolactin lowering drug bromocriptine: comparison with hydroxychloroquine in a randomized, blinded one-year study. Arthritis Rheum 1999; 42: S282.
48. Leiderman S, Gurfinkiel M, Damilano S, et al. Prolactin and IgG-prolactin complex levels in patients with rheumatic arthritis. Ann N Y Acad Sci 2002; 966: 252-7.
49. Seriolo B, Ferretti V, Sulli A, Fasciolo D, Cutolo M. Serum prolactin concentrations in male patients with rheumatoid arthritis. Ann N Y Acad Sci 2002; 966: 258-62.
50. Templ E, Koeller M, Riedl M, Wagner O, Graninger W, Luger A. Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Br J Rheumatol 1996; 35: 350-56.
51. Jorgenson C, Bressot N, Bologna C, Sany J. Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. J Rheumatol 1995; 22: 1829-33.
52. Halko G, Urrows S, Affleck G, Waterman J. Serum prolactin levels and disease activity in rheumatoid arthritis. Arthritis Rheum 1995; 38: S289.
53. Ram S, Blumberg D, Newton P, Anderson N, Gama R. Raised serum prolactin in rheumatoid arthritis: genuine or laboratory artefact? Rheumatology 2004; 43: 1272-74.
54. Dougados M, Duchesne L, Amor B. Bromocriptine and cyclosporin A combination therapy in rheumatoid arthritis. Arthritis Rheum 1988; 31: 1333-34.
55. Marguerie C, David J, So A, Walport M. A pilot study comparing bromocriptine with D-penicillamine in the treatment of rheumatoid arthritis. Br J Rheumatol 1990; 29 suppl 2: 3.
56. Mader R. Bromocriptine for refractory rheumatoid arthritis. Harefuah 1997; 133: 527-29.
57. Figueroa F, Carrion F, Martinez M, Rivero S, Mamani I. Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 1997; 36: 1022-27.
58. Eijsbouts A, van den Joogen F, Laan R, Hermus A, Sweep F, van de Putte L. Treatment of rheumatoid arthritis with the dopamine agonist quinagolide. J Rheumatol 1999; 26: 2284-85.
59. Erb N, Pace A, Delamere J, Kitas G. Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline. Rheumatology 2001; 40: 237-39.
60. Bravo G, Zazueta B, Lavalle C. An acute remission of Reiter's syndrome in male patients treated with bromocriptine. Journal of Rheumatology 1992; 19: 747-50.
61. Sanchez Regana M, Millet P. Psoriasis in association with prolactinoma: three cases. Br J Dermatol 2000; 143: 864-67.
62. Weber G, Frey H. Treatment of psoriasis arthropathica with bromocriptine. Z Hautkr 1986; 61: 1456-66.
63. Eulry F, Bauduceau B, Mayaudon H, Lechevalier D, Ducorps M, Magnin J. Therapeutic efficacy of bromocriptine in psoriatic arthritis (two case-reports). Rev Rheum Engl Ed 1995; 62: 607-8.
64. Buskila D, Sukenik S, Holcberg G, Horowitz J. Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia. J Rheumatol 1991; 18: 611-2.
65. Eulry F, Mayaudon H, Bauduceau B, et al. Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine. Ann Med Interne (Paris) 1996; 147: 15-9.
66. Eulry F, Mayaudon H, Lechevalier D, et al. Treatment of rheumatoid psoriasis with bromocriptine. Presse Med 1995; 24: 1642-4.
67. Weber G, Frey H. Treatment of psoriatic arthritis with bromocriptine. J Am Acad Dermatol 1987; 16: 388-89.
68. Zierhut M, Thiel HJ, Pleyer U, Waetjen R, Weidle EG. Bromocriptine in therapy of chronic recurrent anterior uveitis. Fortschr Ophthalmol 1991; 88: 161-4.
69. Nussenblatt R. Basic and clinical immunology in uveitis. Jpn J Ophthalmol 1987; 31: 368-74.
70. Hedner L, Bynke G. Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol 1985; 100: 618-19.
71. Blank M, Palestine A, Nussenblatt R, Shoenfeld Y. Downregulation of autoantibody levels of cyclosporine and bromocriptine treatment in patients with uveitis. Clin Immunol Immunopathol 1990; 54: 87-97.
72. Palestine A, Nussenblatt R. The effect of bromocriptine on anterior uveitis. Am J Ophthalmol 1988; 106: 488-89.
73. Palestine A, Nussenblatt R, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc 1988; 20 (suppl 4): 131-35.
74. Gutierrez MA, Anaya J, Scopelitis E, Citera G, Solveira L, Espinoza LR. Hyperprolactinemia in primary Sjogren's syndrome? Ann Rheum Dis 1994; 53: 425-28.
75. Allen SH, Sharp GC, Wang G, et al. Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease. Lupus 1996; 5: 30-7.
76. Alekperov R, Nasonov E, Masenko V, Guseva N. Prolactin levels in patients with systemic scleroderma. Klin Med (mosk) 1998; 76: 25-29.
77. Straub RH, Zeuner M, Lock G, Scholmerich J, Lang B. High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 1997; 36: 426-32.
78. Kucharz EJ, Jarczyk R, Jonderko G, Rubisz-Brezezinska J, Brzezinska-Wcislo L. High serum level of prolactin in patients with systemic sclerosis. Clin Rheumatol 1996; 15: 314.